Trials
1 active
5 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “0.5 g/ml calcium, magnesium, potassium, and sodium oxybates solution taken by mouth”In the company’s words, NCT07625280 on ClinicalTrials.gov
- Tested for
- Narcolepsy, Idiopathic Hypersomnia
- Main trialPhase 3
- “The purpose of this study is to evaluate the efficacy and safety of expanded Xywav dosing regimens in adult participants with narcolepsy or idiopathic hypersomnia (IH).”In the company’s words, NCT07625280 on ClinicalTrials.gov
- Other names
- JZP258
Other drugs for Narcolepsy
- OveporextonTakeda · Phase 3
- ALKS 2680Alkermes, Inc. · Phase 3
- CleminorextonCentessa Pharmaceuticals (UK) Limited · Phase 2/3
- PitolisantHarmony Biosciences · Phase 3
- SamelisantSuven Life Sciences Limited · Phase 3
- E2086Eisai · Phase 2
Coming up1
- 23 Dec 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 23 Dec 2027 | A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH | |
| Phase 4Completed | 15 Nov 2022 | An Interventional Safety Switch Study (Segue Study) of XYWAV in Narcolepsy | |
| Phase 4Completed | 25 Feb 2025 | A Switch Study From High-Sodium Oxybate to Xywav to Evaluate Changes in Blood Pressure in Participants With Narcolepsy | |
| Phase 4Completed | 13 Mar 2025 | A Study to Investigate the Effect of XYWAV on Sleepiness, Polysomnography, and Functional Outcomes in Participants With Idiopathic Hypersomnia or Narcolepsy | |
| Phase 3Completed | 12 Jun 2020 | A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026